S Bank Fund Management Ltd Acquires 125 Shares of Regeneron Pharmaceuticals, Inc. $REGN

by · The Cerbat Gem

S Bank Fund Management Ltd raised its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 12.0% in the second quarter, HoldingsChannel reports. The fund owned 1,163 shares of the biopharmaceutical company’s stock after acquiring an additional 125 shares during the period. S Bank Fund Management Ltd’s holdings in Regeneron Pharmaceuticals were worth $611,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently made changes to their positions in the company. Kingswood Wealth Advisors LLC grew its stake in shares of Regeneron Pharmaceuticals by 1.8% in the first quarter. Kingswood Wealth Advisors LLC now owns 1,084 shares of the biopharmaceutical company’s stock worth $681,000 after purchasing an additional 19 shares during the last quarter. Creative Financial Designs Inc. ADV grew its stake in shares of Regeneron Pharmaceuticals by 9.5% in the first quarter. Creative Financial Designs Inc. ADV now owns 220 shares of the biopharmaceutical company’s stock worth $139,000 after purchasing an additional 19 shares during the last quarter. Private Trust Co. NA grew its stake in shares of Regeneron Pharmaceuticals by 13.1% in the first quarter. Private Trust Co. NA now owns 164 shares of the biopharmaceutical company’s stock worth $104,000 after purchasing an additional 19 shares during the last quarter. Proficio Capital Partners LLC grew its stake in shares of Regeneron Pharmaceuticals by 6.2% in the first quarter. Proficio Capital Partners LLC now owns 327 shares of the biopharmaceutical company’s stock worth $207,000 after purchasing an additional 19 shares during the last quarter. Finally, Cove Private Wealth LLC grew its stake in shares of Regeneron Pharmaceuticals by 4.5% in the first quarter. Cove Private Wealth LLC now owns 460 shares of the biopharmaceutical company’s stock worth $292,000 after purchasing an additional 20 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on REGN. Argus cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, June 30th. Weiss Ratings reissued a “hold (c-)” rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 8th. Royal Bank Of Canada boosted their price objective on shares of Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the stock a “sector perform” rating in a research note on Monday, August 4th. Wells Fargo & Company cut shares of Regeneron Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $580.00 price objective on the stock. in a research note on Friday, August 1st. Finally, BMO Capital Markets upped their price target on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the company an “outperform” rating in a research report on Monday, August 4th. Three investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $817.88.

Read Our Latest Stock Report on Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $569.17 on Friday. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $60.33 billion, a P/E ratio of 14.34, a price-to-earnings-growth ratio of 1.85 and a beta of 0.31. The firm’s fifty day simple moving average is $574.34 and its two-hundred day simple moving average is $563.16. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $1,013.09.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last issued its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, beating analysts’ consensus estimates of $8.43 by $4.46. The business had revenue of $3.68 billion for the quarter, compared to analysts’ expectations of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The business’s quarterly revenue was up 3.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $11.56 earnings per share. As a group, analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend was Monday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio is 8.87%.

Regeneron Pharmaceuticals Company Profile

(Free Report)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Recommended Stories

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report).